Clinical Trial Update: Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ablative stereotactic radiotherapy combined with durvalumab (MEDI4736) in Stage I non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Vastra Gotaland Region | Conditions: NSCLC, Stage I | Phase 2 | Status: COMPLETED